Talks on sale of Pfizer's Sandwich R&D hub fall through; Chelsea slides as it proposes new study plan to FDA;

 @FierceBiotech: New strategy from researchers at Penn State reactivates genes to suppress. More | Follow @FierceBiotech

 @JohnCFierce: Pfizer sent me their take on tafamidis just now. No retreat, no surrender. Updated story | Follow @JohnCFierce

 @RyanMFierce: Survey says building "electronic" trials is painfully slow, but that's true for most all clinical trials. More | Follow @RyanMFierce

> Pfizer ($PFE) says that the negotiations on the sale of its big R&D complex in Sandwich, UK have fallen through. Pfizer slashed jobs at the site as part of its overhaul of the research division and will now look for a new buyer. Story

> Chelsea Therapeutics ($CHTP) shares slid this morning after it laid outs its strategy for changing an ongoing study to meet the FDA's demands for more data on Northera (droxidopa), an experimental therapy for neurogenic orthostatic hypotension. Chelsea says it can submit new data in the first quarter of 2013 and has enough cash on hand to make it into the second quarter of next year. Release

> Medivation ($MDVN) and Astellas Pharma announced that they have filed an application with the FDA for their closely-watched cancer drug enzalutamide, formerly known as MDV3100. Release

> Shares of Peregrine Pharmaceuticals ($PPHM) spiked yesterday on mid-stage data demonstrating that its lead drug outperformed chemotherapy in treating lung cancer. Story

Pharma News

 @FiercePharma: J&J's Simponi beat placebo at fighting colitis symptoms, study finds. Possible new use with 700,000 cases, WSJ says. More |  Follow @FiercePharma

> Pharma dealmakers, the price is right for Sweden's Meda. Story

> Private equity owner seeks $510M-plus deal for Germany's Aenova. News

> Bayer's Nexavar falters in another lung cancer trial. Article

Medical Devices News

 @FierceMedDev: Medtronic Q4 earnings jumped just 3%. More | Follow @FierceMedDev

 @MarkHFierce: Please submit your nominations soon for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

> Accuray inks deal with cancer research center. News

> Device industry: Purpose of 510(k) changes remains unclear. Article

> Consumer group demands major change in user fee bill. Item

Pharma Manufacturing News

> FDA inspectors cite problems at Impax California plant. News

> Funding would allow FDA to target more foreign plants. More

> Chinese court favors J&J in distribution fight. Article

Biotech Research News

> Malaria's genetic secrets open door to new drug targets. Story

> Celery extract shrinks difficult breast cancer tumor in mouse trials. Article

> New strategy reactivates genes to suppress cancer. Report

> Researchers find novel way to treat anxiety. More

> Gene therapy = fountain of youth in mice. Item

And Finally… A new study indicates that alcohol can either help or hurt when it comes to developing Alzheimer's, depending on how much a person drinks. Release

 

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.